ID   COLO 824
AC   CVCL_1136
SY   COLO-824; Colo-824; Colo 824; COLO #824; COLO824; Colo824; Colorado 824
DR   CLO; CLO_0002577
DR   CLDB; cl870
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 850
DR   BioSample; SAMN03471347
DR   BioSample; SAMN03473374
DR   cancercelllines; CVCL_1136
DR   Cell_Model_Passport; SIDM00954
DR   ChEMBL-Cells; CHEMBL3308725
DR   ChEMBL-Targets; CHEMBL1075430
DR   CLS; 300463
DR   Cosmic; 906812
DR   Cosmic-CLP; 906812
DR   DepMap; ACH-001820
DR   DSMZ; ACC-200
DR   DSMZCellDive; ACC-200
DR   EGA; EGAS00001000978
DR   GDSC; 906812
DR   GEO; GSM718287
DR   GEO; GSM783979
DR   GEO; GSM847249
DR   GEO; GSM847459
DR   GEO; GSM843492
DR   GEO; GSM843493
DR   GEO; GSM1669694
DR   IARC_TP53; 21245
DR   LINCS_LDP; LCL-1477
DR   PharmacoDB; COLO824_237_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1136
DR   PubChem_Cell_line; CVCL_1136
DR   Wikidata; Q54814156
RX   PubMed=9892114;
RX   PubMed=10969801;
RX   PubMed=20164919;
RX   PubMed=24176112;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JWGray breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Doubling time: ~60-80 hours (DSMZ=ACC-200).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=85.4%; Native American=0.04%; East Asian, North=1.28%; East Asian, South=0%; South Asian=0%; European, North=5.62%; European, South=7.67% (PubMed=30894373).
CC   Caution: Previously erroneously indicated as originating from a male patient, correct sex assignment from Moore G.E. in a personal communication to the authors of PubMed=9892114.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): CLS=300463; Cosmic-CLP=906812; DepMap=ACH-001820; DSMZ=ACC-200; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11,12 (DepMap=ACH-001820; DSMZ=ACC-200)
ST   CSF1PO: 10,12 (CLS=300463; Cosmic-CLP=906812; PubMed=25877200)
ST   D13S317: 11,12,13
ST   D16S539: 12,13 (DSMZ=ACC-200)
ST   D16S539: 13 (CLS=300463; Cosmic-CLP=906812; DepMap=ACH-001820; PubMed=25877200)
ST   D18S51: 15,18,19 (DSMZ=ACC-200)
ST   D18S51: 15,19 (CLS=300463; DepMap=ACH-001820; PubMed=25877200)
ST   D19S433: 15
ST   D21S11: 28
ST   D2S1338: 21
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 7,7.3,8,11 (DepMap=ACH-001820)
ST   D7S820: 7.3,8,11 (DSMZ=ACC-200)
ST   D7S820: 7.9,8,11 (PubMed=25877200)
ST   D7S820: 8,11 (CLS=300463; Cosmic-CLP=906812)
ST   D8S1179: 12,14
ST   FGA: 22
ST   Penta D: 5,10
ST   Penta E: 7
ST   TH01: 7,9
ST   TPOX: 6,11
ST   vWA: 16
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 38
//
RX   PubMed=9892114; DOI=10.1002/(SICI)1098-2264(199901)24:1<87::AID-GCC13>3.0.CO;2-5;
RA   Savelyeva L., Claas A., An H.-X., Weber R.G., Lichter P., Schwab M.;
RT   "Retention of polysomy at 9p23-24 during karyotypic evolution in human
RT   breast cancer cell line COLO 824.";
RL   Genes Chromosomes Cancer 24:87-93(1999).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//